Search results
-
Roche Holding AG: Funding the Genentech Acquisition
Schill, Michael J.; Durick, Brett; Chambers, DrewCase DARDEN-F-1645-EFinanceThis case examines the decision by the Swiss pharmaceutical Roche Holding AG (Roche) to offer a record $42 billion bond in February 2009. In light of a pending acquisition of US biotechnology leader Genentech, Roche management planned to sell $32 billion in bonds at various maturities from 1 year to 30 years and in three different currencies (US dollar, euro, and British pound). In a context of substantial uncertainty in both world financial mark...Starting at €8.20
-
Kelly Solar
Bodily, Samuel E.; Lipson, Marc L.; Lichtendahl, Kenneth C. Jr.Case DARDEN-F-1614-EFinanceA small start-up company must make additional investments to maximize its firm value. But the company owner will not make this investment unless she can renegotiate outstanding debt claims. Solving this "debt overhang" problem through negotiation is the focus of the case. In this context, students are exposed to a variety of issues: the nature of financial claims, bargaining and negotiation fundamentals, and agency costs of debt.Starting at €8.20
-
Kelly Solar - Teaching Note
Lipson, Marc L.; Bodily, Samuel E.; Lichtendahl, Kenneth C. Jr.Teaching Note DARDEN-F-1614TN-EFinanceTeaching note for product F-1614Starting at €0.00
-
Genzyme/Geltex Pharmaceuticals Joint Venture
Bruner, Robert F.; Bodily, Samuel E.; Jacquet, PierreCase DARDEN-F-1254-EFinanceIn March 1997, an executive vice president of Genzyme Corporation must develop the terms by which the $518 billion (revenue) firm will form a joint venture with a small biotechnology firm to make and market a new drug. The tasks for the decision maker are to estimate the enterprise value of the new joint venture, recommend how large an interest to acquire in the venture, and determine what price to pay for that interest and when. The case may be ...Starting at €8.20